"2024年第一创业聚焦主责主业，多业务协同发力，并且强化突出功能性定位，加强金融'五篇大文 章'服务能力，重点着力特色化、差异化经营，持续构建核心竞争力，经营业绩取得全面提升。"第一创 业相关人士告诉记者。 值得注意的是，年报发布同时，第一创业高管人事也发生调整。其中，第一创业公告聘任1987年出生的 青美平措为公司常务副总裁。同时，聘任1973年出生的陈兴珠为公司副总裁。 前者历任北京国管综合管理部副总经理、投资管理二部副总经理、重大项目投资部副总经理、重大项目 投资部总经理、基金管理部总经理，2023年6月至今任第一创业证券董事，并自2024年6月起任副董事 长，自2024年9月起任深圳第一创业创新资本董事、总经理。 后者则是资深投行人士，其中，2000年10月至2006年9月任中银国际证券投资银行部经理，2006年10月 至2009年6月任瑞银证券投资银行部执行总经理，2009年6月至2013年4月任中银国际证券投资银行部董 事总经理。2013年5月加入一创投行，历任企业融资主管、投资银行部负责人、总经理办公会委员、副 总经理，现任一创投行总经理。 在上述业务动态和这两项人事变动下，北京国管与第一创业 ...

Core Insights - Despite an 11.88% year-on-year decline in revenue to 5.677 billion yuan, the company achieved a significant profit rebound, with total profit increasing by 159.94% to 241 million yuan and net profit attributable to shareholders rising by 122.17% to 103 million yuan, successfully reversing previous losses [1] - The company aims to become a global leader in chemical and technology solutions, focusing on differentiated development and enhancing core competitiveness through a strategy of "focus, foresight, and alliances" [1] Business Segments - The crop protection segment remains the core pillar, contributing 3.590 billion yuan, accounting for 63.25% of total revenue. The company has established a supply chain system covering the entire product lifecycle through its production bases in China, the UK, and Malaysia [2] - The pharmaceutical CDMO segment generated revenue of 1.285 billion yuan, benefiting from the growing demand for outsourced R&D in innovative drugs. The company has formed partnerships with several leading pharmaceutical firms and is expanding its CRO platform [2] Future Strategy - The company plans to expand mature businesses, including small molecule CDMO, starting materials, GMP intermediates, and advanced raw materials. It will also invest in emerging businesses such as peptide CDMO and radioactive drug-related CDMO [3] - Despite revenue pressures, the company maintains a strong commitment to R&D, with R&D expenses reaching 291 million yuan, accounting for 5.13% of revenue. The company holds 160 domestic and international invention patents [3] International Strategy - The company's overseas strategy is proactive, with the UK base serving as a gateway to the European market and the Malaysian project as a key foothold in Southeast Asia. This multi-regional capacity configuration reduces geopolitical risks and allows for customized solutions based on client needs [3] Shareholder Returns - The company returned nearly 98 million yuan to shareholders through cash dividends and share buybacks, representing 94.84% of net profit, demonstrating management's commitment to investor returns [4] - The company has implemented a mechanism for shared interests between shareholders and employees, binding core talent through capital increases and employee stock ownership plans [4] Outlook - The company is positioned for a higher quality leap as a "chemical solutions provider," warranting continued market attention [5]

当金融供给侧结构性改革步入深水区，商业银行正积极探路，以差异化发展锚定航向，开 辟高质量发展的新蓝海。作为扎根首都、辐射全国的城商行，北京银行开启了一场贯穿战 略、服务与创新的深度求索。 1999年的世纪之交，北京银行率先在中关村地区成立了中关村科技园区支行。 此后的26年里，北京银行见 证了"科技中国"的生根、发芽和长叶。 北京银行与时俱进，始终以金融的视角关注着科技的发展创新。 2006年，北京银行开启文化金融之旅，将服务文化产业纳入全行发展战略。 此后近20年里，北京银行打造 多款文化金融服务专属产品，与北京市广电局、文旅局、电影局、文物局、体育局签署战略合作协议，连 续十四年支持北京国际电影节。 2021年，为进一步响应国家"碳达峰""碳中和"政策号召，北京银行成立绿色金融专职团队，制定绿色金融 行动计划，发布绿色金融服务品牌"绿融+"。 以绿色金融推动ESG发展的"生态银行"和以文化金融服务文创企业的"文化银行"，也是北京银行结合国家政策 导向和市场需求规划的两条差异化发展路径。在大力发展科技金融的同时，去年北京银行在绿色金融、文化领 域也取得长足进展。 在科技金融、绿色金融、文化金融差异化发展中的 ...